On November 30, 2021 Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, reported a presentation on Axumin (fluciclovine F 18) at the upcoming 22nd Annual Scientific Meeting in Urologic Oncology (SUO), to be held in Orlando, Fla., from December 1 to 3, 2021 (Press release, Blue Earth Diagnostics, NOV 30, 2021, View Source [SID1234596288]). The Society of Urologic Oncology sponsors this highly interactive meeting where attendees participate in discussions led by internationally renowned urologic oncologists, medical oncologists, and scientists. The meeting includes state-of-the-art translational topics on prostate, kidney, and bladder cancer, as well as strategies in urologic oncology will be discussed.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the selected moderated poster presentation are listed below.
NOTE: Axumin (fluciclovine F 18) injection is FDA-approved for PET imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.
HIGHLIGHTED SCIENTIFIC PRESENTATION
Friday, December 3, 2021
SUO presentations are available at designated times for the meeting in Orlando and through an online virtual platform for those who are unable to attend in person.
Axumin (fluciclovine F 18) presentation
Title:
Impact of 18F-Fluciclovine PET/CT on Plans for ADT in Patients with Biochemical Recurrence of Prostate Cancer; Data Analysis from Two Prospective Clinical Trials
Presenter:
Gerald L. Andriole, MD, Division of Urologic Surgery, Department of Surgery and the Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Mo.
Presentation Time:
8:00 – 9:00 AM ET
Poster No.:
144
Blue Earth Diagnostics invites participants at the 22nd Annual Scientific Meeting in Urologic Oncology to attend the presentation above and visit the Blue Earth Diagnostics Exhibit Booth. For session details and scientific presentation listings, please see the SUO online program here.
Indication and Important Safety Information About Axumin
INDICATION
Axumin (fluciclovine F 18) injection is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.
IMPORTANT SAFETY INFORMATION
Image interpretation errors can occur with Axumin PET imaging. A negative image does not rule out recurrent prostate cancer and a positive image does not confirm its presence. The performance of Axumin seems to be affected by PSA levels. Axumin uptake may occur with other cancers and benign prostatic hypertrophy in primary prostate cancer. Clinical correlation, which may include histopathological evaluation, is recommended.
Hypersensitivity reactions, including anaphylaxis, may occur in patients who receive Axumin. Emergency resuscitation equipment and personnel should be immediately available.
Axumin use contributes to a patient’s overall long-term cumulative radiation exposure, which is associated with an increased risk of cancer. Safe handling practices should be used to minimize radiation exposure to the patient and health care providers.
Adverse reactions were reported in ≤ 1% of subjects during clinical studies with Axumin. The most common adverse reactions were injection site pain, injection site erythema and dysgeusia.
To report suspected adverse reactions to Axumin, call 1-855-AXUMIN1 (1-855-298-6461) or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Full Axumin prescribing information is available at View Source